GlassScriptPhysician profile
William C Dalsey
NPI 1659315307
$1,570.06
in general payments reported to CMS, 2019-2025
13 companies · $551 in 2025
The $551 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $60.10 · 2021: $42.23 · 2022: $225 · 2023: $301 · 2024: $66.79 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.39 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $367.32 | 2019-2024 | Andexxa |
| Instrumentation Laboratory Company | $348.90 | 2025 | |
| Janssen Pharmaceuticals, INC | $240.33 | 2019-2022 | |
| Bioxcel Therapeutics, INC. | $178.87 | 2023 | Igalmi |
| Gilead Sciences, INC. | $121.83 | 2023 | Veklury |
| Abbvie INC. | $120.70 | 2025 | |
| Chiesi USA, INC. | $93.60 | 2021-2025 | Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $28.68 | 2019-2020 | |
| Csl Behring | $16.23 | 2020 | |
| Vapotherm INC | $15.39 | 2021 | |
| Nabriva Therapeutics, Plc | $14.80 | 2020 | |
| Glaxosmithkline, LLC. | $11.75 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dalsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.